0918 ESMO QTs
BioCentury & Getty Images

Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

Sep 19, 2020 | 1:28 AM GMT

Incyte moving into Phase III with PD-1 inhibitor retifanlimab for SCAC
Incyte Corp. (NASDAQ:INCY) reported its PD-1 inhibitor retifanlimab led to an objective response rate of 14% and

Read the full 508 word article

How to gain access

Continue reading with a
two-week free trial.